Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise (VENTED)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04427566|
Recruitment Status : Recruiting
First Posted : June 11, 2020
Last Update Posted : September 25, 2020
Low doses of radiation in the form of chest X-rays have been used to treat people with pneumonia. This treatment was found to be effective by reducing inflammation and with minimal side effects. However, it was an expensive treatment and was eventually replaced with less costly treatments such as antibiotics. Radiation has also been shown in some animal experiments to reduce some types of inflammation.
Some patients diagnosed with COVID-19 pneumonia will experience worsening disease, which can become very serious, requiring the use of a ventilator. This is caused by inflammation in the lung from the virus and the immune system. For this study, the x-ray given is called radiation therapy. Radiation therapy uses high-energy X-ray beams from a large machine to target the lungs and reduce inflammation. Usually, it is given at much higher doses to treat cancers.
The purpose of this study is to find out if adding a single treatment of low-dose x-rays to the lungs might reduce the amount of inflammation in the lungs from a COVID-19 infection, which could help a patient to breathe without use of a ventilator.
|Condition or disease||Intervention/treatment||Phase|
|COVID-19||Radiation: Radiation therapy||Phase 2|
The primary outcome is the mortality rate 30 days after the ICU-based mechanical ventilation initiation.Based on current data available, the mortality rate for ventilated patients is assumed to be 80% in the current design. An interim futility analysis will be conducted after 16 evaluable patients have received the ultralow dose-whole lung radiation therapy (ULD-WLRT). If at least 3 patients survive for at least 30 days, we will enroll additional 8 patients (total of 24 patients). Otherwise, the trial will stop for further evaluation. Due to the limited data currently available in local institutions about a 30 day mortality rate , we will retrospectively evaluate the mortality rate of the ventilated patients without the ULD-WLRT in our institution when data is available.
Time to event secondary objectives (e.g. overall survival, time to discharge) analyses will be performed using Kaplan-Meier survival analysis, with a competing risk model (leaving the study because of death), including effects for demographic/clinical characteristics in the model. Proportional endpoints (such as % patients off ventilator) will be calculated along with the 95% Clopper-Pearson exact confidence interval. Pre/post measurements will be evaluated using linear mixed models for repeated measures (with proper data transformation as needed). Association between demographic/clinical characteristics and other secondary objectives (size of ground glass opacities (GGO)/opacification, for example) will be accomplished with generalized linear models.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Vented COVID: A Phase II Study Of The Use Of Ultra Low-Dose Bilateral Whole Lung Radiation Therapy in the Treatment Of Critically Ill Patients With COVID-19 Respiratory Compromise|
|Actual Study Start Date :||July 23, 2020|
|Estimated Primary Completion Date :||December 31, 2021|
|Estimated Study Completion Date :||December 31, 2021|
Experimental: Radiation Arm
Each subject will receive a dose of whole lung radiation. A second optional dose of 80 cGy may be delivered if no improvement after 3-10 days.
Radiation: Radiation therapy
Patients will be treated with a single dose of 80 cGy to the bilateral lungs in a manner that is simplified such that it can be designed and delivered quickly in one session. No specific normal tissue constraints are employed in this protocol.
- Mortality rate of subjects treated with whole lung low-dose radiation [ Time Frame: up to 28 days post radiation delivery ]Death date of subjects will be collected from the date of radiation up to 1 month post radiation dose
- Survival rate of subjects treated with whole lung low-dose radiation [ Time Frame: up to 18 months post radiation delivery ]Subject survival will be collected in number of days through 18 months post treatment
- Change in number of Intensive care unit days [ Time Frame: up to 28 days post radiation delivery ]Number of intensive care days
- Change in number of days using supplemental oxygen [ Time Frame: up to 28 days post radiation delivery ]Number of days using supplemental oxygen
- Change in oxygenation index/oxygen saturation index for 14 days post treatment or until extubated [ Time Frame: up to 28 days post radiation ]Oxygenation index/oxygen saturation until extubation
- Quantitation of Lung Involvement using Chest CT [ Time Frame: up to 28 days post radiation ]Measure as a percent, the amount of pneumonia involvement of each lung segment (right upper lobe, right middle lobe, right lower lobe, left upper lobe and left lower lobe) from chest CT images at day 7, 14 and 28. Each lung segment can have involvement from 0 % (no involvement) up to 100% (complete pneumonia involvement of segment)
- Quantitation of Lung Opacities using Chest CT [ Time Frame: up to 28 days post radiation ]Semi-quantitation of ground glass opacities or lung opacification with a score of 0-5 from Chest CT images at day 7, 14 and 28 for each of the 5 lobes of the lungs. The scoring system is as follows: 0, no involvement; 1, <5% involvement; 2, 25% involvement, 3, 26-49% involvement; 4, 50-75% involvement; and 5, >75% involvement.
- SARS-CoV2 viral titers [ Time Frame: up to 28 days ]Determine viral titers at baseline, days 7, 14 and 28.
- Incidence of adverse events, including severity and duration, for administration of low dose radiation to lungs [ Time Frame: up to 28 days ]Review adverse events, including severity and duration, for all subjects to determine safety of the radiation treatment for pneumonia due to COVID-19.
- Change in performance status after low dose radiation to lungs [ Time Frame: up to 28 days ]Performance status will be evaluated using the Karnofsky Performance Scale Index at baseline, 7, 14 and 28 days post radiation dose. Scores range from 100 (normal, no complaints) to 0 (dead). A higher number indicates the ability to carry out normal daily activities.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04427566
|Contact: Arnab Chakravarti||614-293-0672||Arnab.Chakravarti@osumc.edu|
|Contact: Kimberly Mahlerfirstname.lastname@example.org|
|United States, Ohio|
|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center||Recruiting|
|Columbus, Ohio, United States, 43210|
|Contact: Arnab Chakravarti, MD 614-293-8415 Arnab.Chakravarti@osumc.edu|
|Principal Investigator: Arnab Chakravarti, MD|
|Principal Investigator:||Arnab Chakravarti||James Cancer Hospital, Department of Radiation Oncology|